159 related articles for article (PubMed ID: 17094470)
1. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models.
Tejeda M; Gaál D; Hullán L; Hegymegi-Barakonyi B; Kéri G
Anticancer Res; 2006; 26(5A):3477-83. PubMed ID: 17094470
[TBL] [Abstract][Full Text] [Related]
2. Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models.
Tejeda M; Gaal D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri GY
Anticancer Res; 2008; 28(5A):2769-74. PubMed ID: 19035308
[TBL] [Abstract][Full Text] [Related]
3. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts.
Tejeda M; Gaal D; Barna K; Csuka O; Kéri G
Anticancer Res; 2003; 23(5A):4061-6. PubMed ID: 14666719
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models.
Tejeda M; Gaál D; Hullán L; Schwab R; Szokoloczi O; Kéri G
Anticancer Res; 2007; 27(6B):4015-9. PubMed ID: 18225564
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models.
Tejeda M; Gaál D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri G
Anticancer Res; 2006; 26(4B):3011-5. PubMed ID: 16886628
[TBL] [Abstract][Full Text] [Related]
6. Influence of various administration routes on the antitumor efficacy ofTT-232, a novel somatostatin analog.
Tejeda M; Gaal D; Schwab RE; Pap A; Szúts T; Keri G
Anticancer Res; 2000; 20(2A):1023-7. PubMed ID: 10810391
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models.
Tejeda M; Gaál D; Csuka O; Kéri G
Anticancer Res; 2005; 25(1A):325-30. PubMed ID: 15816555
[TBL] [Abstract][Full Text] [Related]
8. In vivo antitumor activity of TT-232 a novel somatostatin analog.
Tejeda M; Gaal D; Schwab RE; Pap A; Keri G
Anticancer Res; 1999; 19(4B):3265-8. PubMed ID: 10652622
[TBL] [Abstract][Full Text] [Related]
9. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
[TBL] [Abstract][Full Text] [Related]
10. The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen.
Tejeda M; Gaál D; Csuka O; Ullrich A; Schwab R; Pap A; Horváth A; Kéri G
Cancer Detect Prev; 2003; 27(2):155-62. PubMed ID: 12670528
[TBL] [Abstract][Full Text] [Related]
11. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor effects of a new antitumor agent, zinostatin stimalamer (YM881)--effects on experimental tumors in vitro and in vivo].
Numasaki Y; Takahashi K; Masuda E; Nohara C; Maeda H
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2289-94. PubMed ID: 1834021
[TBL] [Abstract][Full Text] [Related]
14. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours.
Schwab RE; Froidevaux S; Paku S; Tejeda M; Szende B; Pap A; Beglinger C; Eberle AN; Kéri G
Anticancer Res; 2001; 21(1A):71-5. PubMed ID: 11299792
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of 2'-deoxy-2'-methylidenecytidine, a new 2'-deoxycytidine derivative.
Yamagami K; Fujii A; Arita M; Okumoto T; Sakata S; Matsuda A; Ueda T; Sasaki T
Cancer Res; 1991 May; 51(9):2319-23. PubMed ID: 2015596
[TBL] [Abstract][Full Text] [Related]
17. Are syngeneic mouse tumor models still valuable experimental models in the field of anti-cancer drug discovery?
Darro F; Decaestecker C; Gaussin JF; Mortier S; Van Ginckel R; Kiss R
Int J Oncol; 2005 Sep; 27(3):607-16. PubMed ID: 16077908
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the pharmacological antitumor effects of S 12363, a new vinca alkaloid.
Atassi G; Berlion M; el Oche Y; Bizzari JP
Anticancer Res; 1991; 11(2):975-80. PubMed ID: 2064354
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
Krapcho AP; Menta E; Oliva A; Di Domenico R; Fiocchi L; Maresch ME; Gallagher CE; Hacker MP; Beggiolin G; Giuliani FC; Pezzoni G; Spinelli S
J Med Chem; 1998 Dec; 41(27):5429-44. PubMed ID: 9876113
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
MacDonald JR; Muscoplat CC; Dexter DL; Mangold GL; Chen SF; Kelner MJ; McMorris TC; Von Hoff DD
Cancer Res; 1997 Jan; 57(2):279-83. PubMed ID: 9000568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
